Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | USP7 | Q93009 | 4/20 | 0.31 |
| ▸ | HTR1A | P08908 | 4/20 | 0.31 |
| ▸ | HTR7 | P34969 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17192041 | 0.75 | TNF (0.47) | TNFMEN1KMT2AKCNH2LMNA | |
| SCHEMBL17192042 | 0.74 | TNF (0.43) | TNFLMNAHTR1AHTR7TP53 | |
| SCHEMBL17181555 | 0.73 | TNF (0.39) | TNFMEN1KMT2ALMNAMAPT | |
| SCHEMBL17181429 | 0.68 | TNF (0.38) | TNFKMT2AUSP7ALDH1A1 | |
| SCHEMBL15680553 | 0.62 | HDAC6 (0.45) | KMT2AUSP7 | |
| SCHEMBL24879062 | 0.57 | KMT2A (0.51) | TNFMEN1KMT2ALMNAMAPT | |
| SCHEMBL15670992 | 0.56 | TNF (0.41) | TNFMAPT | |
| SCHEMBL30987284 | 0.56 | HSD17B13 (0.38) | USP7USP2ALDH1A1MAPK1 | |
| SCHEMBL15671151 | 0.55 | TNF (0.45) | TNFMAPT | |
| SCHEMBL15670874 | 0.55 | TNF (0.72) | TNFMAPTHTR1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | TNF 2990/4885MEN1 3926/4885KMT2A 1116/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | TNF 1673/4885MEN1 3214/4885KMT2A 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.